Evidence map›Paper›PMID 40750733›Full record

ReviewHormones (Athens, Greece)2026

Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans.

Anna Giannakogeorgou, Michael Roden, Kalliopi Pafili

Abstract readReview
In one paragraph

Review in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Current perspectives on lipid management in diabetic kidney disease: Can fibrates offer advantages over statins for renal outcomes?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anna GiannakogeorgouInstitute of Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
Michael RodenInstitute of Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
Kalliopi PafiliInstitute of Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. kalliopi.pafili@ddz.de.ORCID http://orcid.org/0000-0003-4293-3514

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND & SCOPE OF REVIEW: Diabetes mellitus encompasses a spectrum of metabolic disorders characterized by hyperglycemia. The currently most replicated phenotypic clustering approach, introduced by Ahlqvist et al. and validated by Zaharia et al., identified subtypes based on clinical presentation and underlying pathophysiology. This classification aims at predicting complication risk and enabling targeted therapies. Our review explores shared and distinct mechanisms driving complications, focusing on cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD), both strongly linked to insulin resistance. We also summarize treatment strategies targeting both conditions and outline mechanisms specific to the development of diabetic foot syndrome, exemplifying the continuum from localized to systemic complications.

methodsWe conducted a narrative review of human and translational studies, focusing on mechanisms and treatments across the above phenotype-based diabetes subtypes, given their reproducibility across populations. MAIN

resultsDiabetes is a multisystem disorder involving a cascade of metabolic disturbances. These include mitochondrial adaptations in key metabolically active tissues contributing to systemic and tissue-specific insulin resistance. Inflammation, inadequate immune responses, oxidative stress, and genetic and environmental factors shape the development of comorbidities whose prevalence varies across subtypes. The interplay between MASLD and diabetes forms a vicious cycle of metabolic abnormalities. Novel treatments show promise in both liver and glycemic endpoints.

conclusionPhenotype-based diabetes subtypes exhibit distinct underlying pathophysiological mechanisms which shape the development of complications, with insulin resistance serving as the central link. Targeting these pathways can pave the way for personalized diabetes therapies.

Indexed as

Diabetes ComplicationsDiabetes MellitusFatty LiverHumansInsulin ResistanceCardiovascular diseasesClusteringDiabetes mellitusDiabetes subtypesFatty liverInsulin resistanceMASLDNeuropathy

Identifiers

PMID40750733
PMCPMC13013133

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.